The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis

McGirr, Ashleigh; Widenmaier, Robyn; Curran, Desmond; Espié, Emmanuelle; Mrkvan, Tomáš; Oostvogels, Lidia; Simone, Benedetto; McElhaney, Janet E.; Burnett, Heather; Haeussler, Katrin; Thano, Adriana; Wang, Xuan; Newson, Rachel S.

doi:10.1016/j.vaccine.2019.04.014

Cited by 35 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two licensed injectable HZVs, a live attenuated HZV (ZVL) 9 and an adjuvant recombinant subunit vaccine (HZ/su) 10 are used to prevent HZ and PHN in the older population, reducing the risk of HZ by 50%. The ZVL and the recombinant HZV were both compared in a large meta-analysis of the general population and found to be superior to placebo in the prevention of shingles 11 , 12 and PHN. 12 …”

mentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD

Hamad

Allam

Sulaiman

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

mentioning

confidence: 99%

“…The ZVL and the recombinant HZV were both compared in a large meta-analysis of the general population and found to be superior to placebo in the prevention of shingles 11 , 12 and PHN. 12 …”

mentioning

confidence: 99%

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD

Hamad

Allam

Sulaiman

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

show abstract

“…There has been no head-to-head study that directly compares LZV and RZV vaccine efficacy and safety; only an indirect comparison between RZV and LZV is available. One such study is a network meta-analysis performed by Glax-oSmithKline in which RZV was compared to LZV in terms of efficacy and safety for HZ and PHN prevention [38]. In this study, RZV showed significantly higher efficacy compared to LZV in HZ prevention in adults ≥ 60 years (92% for RZV vs. 51% for LZV).…”

Section: ) Rzv Shingrix ®mentioning

confidence: 89%

Recombinant zoster vaccine (Shingrix^®): a new option for the prevention of herpes zoster and postherpetic neuralgia

et al. 2020

View full text Add to dashboard Cite

“…There is some evidence that Shingrix is more effective at preventing shingles and reducing the frequency of post-herpetic neuralgia in patients over the age of 60 years than the live vaccine. 3…”

Section: Key Pointsmentioning

confidence: 99%

Cutaneous manifestations of infections: an update for general physicians

Morris‐Jones

2021

Clinical Medicine

View full text Add to dashboard Cite

Infection rashes can present in a number of different ways, some giving a reactive pattern in the skin to infection elsewhere in the body, while others reflect infection within the affected skin itself. Recognising the possible systemic symptoms, characteristic distribution and morphology of rashes can lead to a high degree of accuracy in making a clinical diagnosis in the clinic room/at the bedside that can be confirmed with a few simple laboratory tests. Cutaneous manifestations of SARS-CoV-2 (COVID-19)There are five main skin manifestations of COVID-19 infection in adults, the prevalence of skin manifestations has been estimated to be between 0.4-20%. 1 The three main skin presentations are similar to those you might see with other systemic viral infections, maculopapular rash (similar to what you might see in measles), vesicles (chicken pox-like blisters) and urticaria (hives). These rashes occur at the same time as viral symptoms and are usually associated with mild to moderate symptoms of COVID-19. 'COVID-toes' are a late manifestation of usually very mild SARS-CoV-2 infection (patients may otherwise be asymptomatic) and present with chilblain-like lesions on the toes, fingers and elbows (Fig 1). There is dusky purplish erythema and blistering which may be asymptomatic and is thought to be due to microthrombi caused by the virus within the endothelial cells. The fifth cutaneous manifestation is livedoid/retiform purpura which is associated with more severe COVID-19 disease (thrombotic vasculopathy) and usually occurs at the same time or later in the course of the COVID-19 infective illness. There is no specific skin directed treatment needed for any of these cutaneous manifestations.

show abstract

The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis

Cited by 35 publications

References 36 publications

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD

Recombinant zoster vaccine (Shingrix^®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Cutaneous manifestations of infections: an update for general physicians

Contact Info

Product

Resources

About

The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis

Cited by 35 publications

References 36 publications

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Cutaneous manifestations of infections: an update for general physicians

Contact Info

Product

Resources

About

Recombinant zoster vaccine (Shingrix^®): a new option for the prevention of herpes zoster and postherpetic neuralgia